The Health Technology Assessment Review options paper includes a line that explains why any stakeholder push to widen how technologies are valued faces such strong institutional resistance.
'A broader assessment of value would increase the cost and reduce the benefit to us'
February 6, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
It is profoundly wrong for any system to exclude compassion while outsourcing it to others
March 16, 2026 - - Latest News -
Scientists identify highly specific targets that could transform multiple myeloma treatment
March 15, 2026 - - Australian Biotech -
CSL Seqirus' adjuvanted flu vaccine approval extended to Australians aged 50 and over
March 15, 2026 - - Latest News -
GSK claims Pharma Cup as Kosi Challenge surpasses fundraising record
March 15, 2026 - - Latest News -
New program aims to make women’s health care more affordable and accessible
March 13, 2026 - - Latest News -
Australians turn to local pharmacies as frontline of everyday healthcare
March 13, 2026 - - Latest News -
Sandoz and Camp Quality unite to strengthen support for Australian families facing childhood cancer
March 13, 2026 - - Latest News

